
NYSE:CVS
Price target was raised today. This peaked in 2020-1 then was hit with a lot of bad news, like doubts over Signify and Oak Street acquisitions. But that negative sentiment has reversed, like their Medicare Advantage stars rating has gone up, and the street sees profitability rising in their pharmacy benefits management system, based on a new model last month. Trades under a cheap PE and pays a 3% dividend. He targets over $100 in 12 months. Is underloved and over-owned.
Healthcare has lagged this year. They run a chain of pharmacies, Aetna health insurance, pharmacy management and recently bought Oak Health. The CEO is doing a great job, and shares are not expensive around 8.5x PE. They took one some debt to bought some companies, but once they integrated them, it will ramp up cash flow.
(Analysts’ price target is $87.45)CVS Health Corp is a American stock, trading under the symbol CVS (previously CVS-N on Stockchase) on the New York Stock Exchange (CVS). It is usually referred to as NYSE:CVS or CVS
In the last year, there was no coverage of CVS Health Corp published on Stockchase.
CVS Health Corp was recommended as a Top Pick by The Weekly Buzzing Stocks by Billy Kawasaki on 2023-09-14. Read the latest stock experts ratings for CVS Health Corp.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered CVS Health Corp in the last year. It is a trending stock that is worth watching.
On 2026-06-05, CVS Health Corp (CVS) stock closed at a price of $95.93.
Bought at less than 10x earnings with recent dividend increase is good for share price appreciation. Recent M&A also good for investors. Will continue to own shares. Excellent management team and solid dividend. Weakness is sector creating opportunities to buyout competitors.